About

Sensei Biotherapeutics is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer and other diseases.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. We are utilizing two unique drug discovery approaches. The first approach is our ImmunoPhage™️ platform, that generates powerful, self-adjuvanted, and specific immune responses. Our most advanced ImmunoPhage™️ program, SNS-301, is currently enrolling patients in a Phase 1/2 clinical trial, as a potential treatment for squamous cell carcinoma of the head and neck (SCCHN). An additional ImmunoPhage™️ program includes SNS-401, an ImmunoPhage™️ cocktail for the treatment of Merkel Cell Carcinoma. We plan to submit an investigation new drug submission in the first half of 2022 for this product candidate. The second approach is our monoclonal antibody (mAb) and nanobody platform, which are comprised of unique human monoclonal antibodies and alpaca-derived nanobodies that are selectively active in the tumor microenvironment. SNS-VISTA is our most advanced antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). IND-enabling studies for SNS-VISTA are expected by the end of 2021. Through the targeted use of these programs, we believe we can further enhance therapeutic activity.